Understanding how young people with HIV in Ghana respond to a new treatment
Official title: PHARMACOKINETICS AND PHARMACOGENOMICS OF DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY IN YOUNG PEOPLE LIVING WITH HIV IN GHANA (PHARMA-YOUNG-HIV)
Funded at University of Ghana Medical Centre · NIH-11007344 · Data updated 2026-11-12
This study is looking at how well young people with HIV in Ghana respond to a newer HIV medication called dolutegravir, to see how it works for them and if there are any side effects, so we can make their treatment better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Ghana Medical Centre NIH-funded |
| Lab location | 1 site (Accra, Ghana) |
| Project start | August 16, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $153,912 |
| NIH project number | 1R21AI186750-01 |
| Project ID | NIH-11007344 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are young people aged 10-24 years living with HIV in Ghana who are receiving dolutegravir-based therapy.
✕Less likely to help
Patients outside the age range of 10-24 years or those not receiving dolutegravir-based therapy may not benefit from this research.
What this research studies
This research investigates how young people living with HIV in Ghana metabolize dolutegravir-based antiretroviral therapy. It aims to understand the effectiveness and potential side effects of this treatment in a population that has recently switched from older medications. By studying drug concentrations and patient responses, the research seeks to identify any issues related to treatment adherence and adverse effects. The findings could help improve treatment strategies for young people with HIV in sub-Saharan Africa.
Why it matters
Potential benefit: If successful, this research could lead to better treatment protocols for young people living with HIV, enhancing their health outcomes.
How similar studies have gone: While there have been studies on dolutegravir in adults, this specific focus on young people in Ghana is novel and has not been extensively tested.
Where this research is happening
-
University of Ghana Medical Centre
Accra, Ghana Active
Researchers
- Principal investigator: Thomford, Nicholas Ekow — University of Ghana Medical Centre
- Study coordinator: Thomford, Nicholas Ekow
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding how broadly neutralizing antibodies may help HIV cure trials
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.